Skip to main content
Clinicians now have a dedicated continuous use oral contraceptive. The Food and Drug Administration (FDA) has given final approval to Lybrel from Wyeth Pharmaceuticals of Collegeville, PA. The drug represents the first combination contraceptive pill designed to be taken 365 days a year, without a placebo phase or pill-free interval.

Continuous use oral contraceptive receives FDA regulatory approval

July 1, 2007

Clinicians now have a dedicated continuous use oral contraceptive. The Food and Drug Administration (FDA) has given final approval to Lybrel from Wyeth Pharmaceuticals of Collegeville, PA. The drug represents the first combination contraceptive pill designed to be taken 365 days a year, without a placebo phase or pill-free interval.
Article Limit Reached

You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.

  • Award-winning Medical Content
  • Latest Advances & Development in Medicine
  • Unbiased Content
View Subscription Details

Already have an account? Log in